Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Exploring the molecular mechanisms of comorbidity between thyroid cancer and breast cancer through multi-omics data.Scientific reports · 2025
   Article
2. Circular Nucleic Acids Act as an Oncogenic MicroRNA Sponge to Inhibit Hepatocellular Carcinoma Progression.Biomedicines · 2025
   Article
3. ANGPTL1 attenuates cancer migration, invasion, and stemness through regulating FOXO3a-mediated SOX2 expression in colorectal cancer.Clinical science (London, England : 1979) · 2022
   Article
4. ANGPTL1 is a potential biomarker for differentiated thyroid cancer diagnosis and recurrence.Oncology letters · 2020
   Article
5. Cord Blood Levels of Angiopoietin-Like 7 (ANGPTL7) in Preterm Infants.BioMed research international · 2020
   Article

Corrections and comments

• Erratum for
  Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility.2013

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.